Delayed mid-stage data show promise for French company

French firm Abionyx Pharma (Euronext: ABNX) has reported positive interim results from an open-label Phase IIa trial of its acute kidney injury (AKI) candidate CER-001.

The company, which is focused on developing innovative medicines in indications where there is no effective or existing treatment, believes CER-001 has potential as an option for septic patients at high risk of developing AKI.

Compared to standard of care therapy, CER-001 rapidly improved biomarkers of inflammation, preventing septic patients’ decline into AKI, the company said.